Unlike other synNotch research where the focusis engineering immune cells to target cancer cells, this study aimsto engineer cancer cells with a macrophage-sensitive synNotch receptortargeting CD206, a surface marker specific to pro-tumorigenic macrophagesubsets. The gene discussed is MRC1; the disease is cancer.